INOVIOPossible readd on a retracement if we find support at retracement levels. Could break out of wedge structure and long way to find resistance on macro levels
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.591CHF
−113.76 MCHF
700.50 KCHF
25.74 M
About Inovio Pharmaceuticals, Inc.
Sector
CEO
Jacqueline E. Shea
Headquarters
Plymouth Meeting
Website
Founded
1983
FIGI
BBG00LVDLC19
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
INO Inovio Pharmaceuticals Options Ahead of EarningsAnalyzing the options chain and the chart patterns of INO Inovio Pharmaceuticals prior to the earnings report this week,
I would consider purchasing the 13usd strike price Calls with
an expiration date of 2024-5-17,
for a premium of approximately $0.25.
If these options prove to be profitable prior
$INO 50% upside potentialNASDAQ:INO had a streak of green weeks recently and currently is trading above a significant resistance at $11.96
- MACD weekly just turned positive
- Vortex index is positive
INO 1D 2 Month Larger TF shows continuation. Time/Space corrective until wave (B). Breakout of falling wedge finished. Retracement and continuation.
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases a
INO Bullish Deep CrabINO has completed a bottom formation IMO. I believe the bottom has come in a harmonic deep crab formation. I've highlighted the accumulation zone. This is high risk but also has the potential of being a 5 to 100x bagger. Good Luck!
💊 INO SELL THE BREAK 📉INO has broken out of a larger degree correction and continues to make smaller degree flags in the bearish direction.
Stick to your trading rules!
Inovio timeCovid is here to stay!
Data from the WHO will be good. Time to buy and hold. Let the shorts
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of GBM is 5.010 CHF — it has decreased by −57.11% in the past 24 hours. Watch INOVIO PHARMACEUTI stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange INOVIO PHARMACEUTI stocks are traded under the ticker GBM.
GBM stock has fallen by −57.11% compared to the previous week, the month change is a −57.11% fall, over the last year INOVIO PHARMACEUTI has showed a −57.11% decrease.
We've gathered analysts' opinions on INOVIO PHARMACEUTI future price: according to them, GBM price has a max estimate of 28.14 CHF and a min estimate of 5.97 CHF. Watch GBM chart and read a more detailed INOVIO PHARMACEUTI stock forecast: see what analysts think of INOVIO PHARMACEUTI and suggest that you do with its stocks.
GBM stock is 133.17% volatile and has beta coefficient of 1.93. Track INOVIO PHARMACEUTI stock price on the chart and check out the list of the most volatile stocks — is INOVIO PHARMACEUTI there?
Today INOVIO PHARMACEUTI has the market capitalization of 126.30 M, it has decreased by −2.74% over the last week.
Yes, you can track INOVIO PHARMACEUTI financials in yearly and quarterly reports right on TradingView.
INOVIO PHARMACEUTI is going to release the next earnings report on Nov 5, 2024. Keep track of upcoming events with our Earnings Calendar.
GBM earnings for the last quarter are −1.07 CHF per share, whereas the estimation was −0.99 CHF resulting in a −8.02% surprise. The estimated earnings for the next quarter are −0.97 CHF per share. See more details about INOVIO PHARMACEUTI earnings.
INOVIO PHARMACEUTI revenue for the last quarter amounts to 90.59 K CHF, despite the estimated figure of 120.47 K CHF. In the next quarter, revenue is expected to reach 95.62 K CHF.
GBM net income for the last quarter is −28.98 M CHF, while the quarter before that showed −27.49 M CHF of net income which accounts for −5.44% change. Track more INOVIO PHARMACEUTI financial stats to get the full picture.
No, GBM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 19, 2024, the company has 122.00 employees. See our rating of the largest employees — is INOVIO PHARMACEUTI on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INOVIO PHARMACEUTI EBITDA is −102.78 M CHF, and current EBITDA margin is −15.83 K%. See more stats in INOVIO PHARMACEUTI financial statements.
Like other stocks, GBM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INOVIO PHARMACEUTI stock right from TradingView charts — choose your broker and connect to your account.